MedPath

Phenylalanine

Generic Name
Phenylalanine
Brand Names
Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinimix 2.75/5, Clinimix E 2.75/5, Clinisol 15, Freamine 6.9, Freamine III 10, Hepatamine 8, Nephramine, Olimel, Periolimel, Plenamine, Premasol, Primene, Procalamine 3, Prosol, Travasol 10, Trophamine 10 %
Drug Type
Small Molecule
Chemical Formula
C9H11NO2
CAS Number
63-91-2
Unique Ingredient Identifier
47E5O17Y3R
Background

Phenylalanine is an essential aromatic amino acid that is a precursor of melanin, dopamine, noradrenalin (norepinephrine), and thyroxine.

Indication

L-phenylalanine may be helpful in some with depression. It may also be useful in the treatment of vitiligo. There is some evidence that L-phenylalanine may exacerbate tardive dyskinesia in some schizophrenic patients and in some who have used neuroleptic drugs.

Associated Therapies
Amino acid supplementation
Clinical Trials
Related News

Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia

Phase 2
Completed
Conditions
Presbyopia
Interventions
Drug: BRIMOCHOL™
First Posted Date
2021-03-01
Last Posted Date
2025-02-05
Lead Sponsor
Visus Therapeutics
Target Recruit Count
18
Registration Number
NCT04774237
Locations
🇺🇸

Total Eye Care, PA, Memphis, Tennessee, United States

🇺🇸

Global Research Management, Inc., Glendale, California, United States

🇺🇸

Eye Research Foundation, Newport Beach, California, United States

Evaluation of the Fluoride Dose Response Using In Situ Caries Model

Phase 4
Completed
Conditions
Caries
Interventions
Drug: 1100 ppm SnF2
First Posted Date
2021-02-21
Last Posted Date
2022-07-19
Lead Sponsor
Procter and Gamble
Target Recruit Count
15
Registration Number
NCT04763044
Locations
🇺🇸

Oral Health Research Institute, Indianapolis, Indiana, United States

Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)

Recruiting
Conditions
Alzheimer Disease
Interventions
Drug: [11C]-Pittsburgh Compound B ([11C]PiB)
First Posted Date
2020-10-08
Last Posted Date
2024-07-17
Lead Sponsor
Tammie L. S. Benzinger, MD, PhD
Target Recruit Count
650
Registration Number
NCT04579120
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

A Study to Evaluate Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of IN-C005 in Healthy Male Subjects

Phase 1
Conditions
Healthy
Interventions
Drug: IN-C005 dose E
Drug: IN-C005 dose B
Drug: IN-C005 dose A
Drug: IN-C005 dose C
First Posted Date
2020-07-24
Last Posted Date
2020-11-09
Lead Sponsor
HK inno.N Corporation
Target Recruit Count
42
Registration Number
NCT04485884
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CJ-15314 Phosphate in Healthy Male Subjects

Phase 1
Conditions
Healthy
Interventions
Drug: A dose as CJ-15314
Drug: B dose as CJ-15314
Drug: C dose as CJ-15314
Drug: E dose as CJ-15314
Drug: Placebo
First Posted Date
2020-03-06
Last Posted Date
2020-03-06
Lead Sponsor
HK inno.N Corporation
Target Recruit Count
55
Registration Number
NCT04297865
Locations
🇰🇷

Seoul National University Hospital, Dept. of Clinical Pharmacology, Seoul, Korea, Republic of

Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Treatment A
Drug: Treatment B
Drug: Treatment C
Drug: Treatment E
Drug: Treatment G
Drug: Treatment H
First Posted Date
2019-06-06
Last Posted Date
2019-11-15
Lead Sponsor
Pfizer
Target Recruit Count
25
Registration Number
NCT03978143
Locations
🇺🇸

Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

PK Linearity and Steady State PK of CHF 6532 in Healthy Subjects

Phase 1
Completed
Conditions
Asthma
Interventions
Drug: Treatment A
Drug: Treatment B
Drug: Treatment C
Drug: Treatment E
First Posted Date
2019-05-08
Last Posted Date
2020-07-22
Lead Sponsor
Chiesi Farmaceutici S.p.A.
Target Recruit Count
30
Registration Number
NCT03942666
Locations
🇧🇪

SGS Life Sciences - Clinical Pharmacology Unit Antwerpen, Antwerp, Belgium

Imaging of Brain Structural/Functional Connectivity and Amyloid and Tau Lesions in APOE4 Carriers.

Withdrawn
Conditions
Alzheimer Disease
Interventions
First Posted Date
2019-01-25
Last Posted Date
2024-03-13
Lead Sponsor
Tammie L. S. Benzinger, MD, PhD
Registration Number
NCT03816228
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers

Phase 1
Completed
Conditions
HIV Infections
Interventions
Drug: Treatment A
Drug: Treatment B
Drug: Treatment E
Drug: Treatment C
First Posted Date
2018-02-22
Last Posted Date
2019-12-09
Lead Sponsor
ViiV Healthcare
Target Recruit Count
36
Registration Number
NCT03441984
Locations
🇺🇸

GSK Investigational Site, Austin, Texas, United States

Oral Administration of Tannins and Flavonoids in Children With Acute Diarrhea

Phase 4
Completed
Conditions
Acute Diarrhea
Interventions
Drug: Standard Oral Rehydration
First Posted Date
2017-11-29
Last Posted Date
2017-11-29
Lead Sponsor
Federico II University
Target Recruit Count
60
Registration Number
NCT03356327
Locations
🇮🇹

Marina Russo, Napoli, Italy

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy